Skip to main content
Premium Trial:

Request an Annual Quote

USPTO to Issue RXi siRNA Sequence-Specific Patents


RXi Pharmaceuticals this week said it has received notices of allowance from the US Patent and Trademark Office on patent applications, filed by Thermo Fischer Scientific and licensed to RXi, covering siRNA sequences against a number of gene targets.

Specifically, the applications cover siRNAs targeting superoxide dismutase, amyloid beta precursor protein, interleukin-1 receptor-associated kinase 4, hepatocyte growth factor receptor, and cyclin-dependent kinase inhibitor p27, RXi said.

"These sequence-specific patent applications and the ones we expect to follow add another important component to our robust intellectual property portfolio," RXi President and CEO Tod Woolf said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.